Yiling Jiang
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.
Journal: PharmacoEconomics
Published: March 17, 2023
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.
Journal: PharmacoEconomics
Published: June 19, 2022
Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States.
Journal: Infectious diseases and therapy
Published: January 16, 2022
A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US.
Journal: Advances in therapy
Published: December 10, 2020
Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States.
Journal: Infectious diseases and therapy
Published: October 01, 2020
Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective.
Journal: Journal of medical virology
Published: May 12, 2020
Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZVIN) trial.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: November 14, 2019
Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.
Journal: Advances in therapy
Published: August 14, 2018
A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.
Journal: Journal of medical economics
Published: May 04, 2018
Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: May 22, 2017
Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.
Journal: BMC public health
Published: March 12, 2016
A comparative public health and budget impact analysis of pneumococcal vaccines: The French case.
Journal: Human vaccines & immunotherapeutics
Published: August 13, 2015
Last Updated: 09/26/2026